Sequential methotrexate and 5-fluorouracil in the treatment of non-small cell carcinoma of the lung.
The sequential administration of methotrexate (MTX) and 5-fluorouracil (5-FU) has been claimed to be synergistic. To investigate the potential synergism in non-small cell carcinoma of the lung (NSCCL), 16 patients were treated with a 2-hr infusion of MTX 200 mg/m2 followed after 2 hr by 5-FU 1g/m2. All patients had an Eastern Cooperative Oncology Group performance status of greater than 2 and had received no previous chemotherapy. No responses were seen. This study demonstrates that sequential MTX and 5-FU in this dosage and schedule is ineffective in NSCCL.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008727:Methotrexate / Q000008:administration & dosage
D005472:Fluorouracil; D008727:Methotrexate